MedPath

Janssen LP

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder

Phase 3
Completed
Conditions
Schizophrenia
Psychotic Disorders
First Posted Date
2005-10-12
Last Posted Date
2011-05-17
Lead Sponsor
Janssen, LP
Target Recruit Count
86
Registration Number
NCT00236353

A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder

Phase 4
Completed
Conditions
Schizophrenia
Diabetes Mellitus
Interventions
First Posted Date
2005-10-12
Last Posted Date
2011-05-17
Lead Sponsor
Janssen, LP
Target Recruit Count
59
Registration Number
NCT00236379

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

Phase 3
Completed
Conditions
HIV Infections
Histoplasmosis
Blastomycosis
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Janssen, LP
Target Recruit Count
60
Registration Number
NCT00002159
Locations
🇺🇸

Community Hosp, Indianapolis, Indiana, United States

🇺🇸

LSU Med Ctr / Div of Pulmonary & Critical Care Med, Shreveport, Louisiana, United States

🇺🇸

Univ of Arkansas for Med Sciences, Little Rock, Arkansas, United States

and more 6 locations

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

Not Applicable
Completed
Conditions
Candidiasis, Oral
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Janssen, LP
Registration Number
NCT00002341
Locations
🇺🇸

Buckley Braffman Stern Med Associates, Philadelphia, Pennsylvania, United States

Study of Itraconazole in Patients With Advanced HIV Infection

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Janssen, LP
Target Recruit Count
36
Registration Number
NCT00002370
Locations
🇺🇸

Erie County Med Ctr / Pharmacy D, Buffalo, New York, United States

A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients

Not Applicable
Completed
Conditions
HIV Infections
Histoplasmosis
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Janssen, LP
Registration Number
NCT00002438
Locations
🇺🇸

Infectious Diseases Research Clinic / Indiana Univ Hosp, Indianapolis, Indiana, United States

🇺🇸

Infectious Diseases of Indianapolis, Indianapolis, Indiana, United States

🇺🇸

Infectious Diseases Association / Research Med Ctr, Kansas City, Missouri, United States

and more 4 locations

A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS

Not Applicable
Completed
Conditions
Cryptosporidiosis
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Janssen, LP
Registration Number
NCT00002278
Locations
🇺🇸

Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States

🇺🇸

Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States

🇺🇸

Cornell Univ Med Ctr, New York, New York, United States

An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.

Not Applicable
Completed
Conditions
Candidiasis, Oral
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Janssen, LP
Registration Number
NCT00002133
Locations
🇺🇸

Pennsylvania Hosp, Philadelphia, Pennsylvania, United States

🇺🇸

Infectious Disease Clinic, Nashville, Tennessee, United States

🇺🇸

Ohio State Univ Hosp, Columbus, Ohio, United States

and more 15 locations

Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)

Not Applicable
Completed
Conditions
Cryptosporidiosis
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Janssen, LP
Target Recruit Count
60
Registration Number
NCT00002027
Locations
🇺🇸

Cornell Univ Med Ctr, New York, New York, United States

🇺🇸

Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States

🇺🇸

Dr Douglas Dieterich, New York, New York, United States

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

Phase 3
Completed
Conditions
Alzheimer Disease
First Posted Date
1999-11-01
Last Posted Date
2005-06-24
Lead Sponsor
Janssen, LP
Registration Number
NCT00000172
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

🇺🇸

VAPS Health Care System, Seattle, Washington, United States

🇺🇸

Indiana Alzheimer's University Clinic, Indianapolis, Indiana, United States

and more 52 locations
© Copyright 2025. All Rights Reserved by MedPath